Alireza Nami

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Brad H. Rovin, Neil Solomons, William F. Pendergraft et al. · Kidney International · 2018 · 290 citations

Dose-ranging Voclosporin, Glomerulonephritis, Autoimmune Disease +12

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

Saira Z. Sheikh, Morton Scheinberg, James Cheng‐Chung Wei et al. · The Lancet Rheumatology · 2020 · 39 citations

Rheumatology, Adverse Events, Autoimmune Disease +9

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Ian N Bruce, Alireza Nami, Erik Schwetje et al. · The Lancet Rheumatology · 2020 · 24 citations

Autoimmune Disease, Scleroderma, Systemic Lupus Erythematosus Treatment +13